BridgeBio Oncology Therapeutics (BBOT) Other Accumulated Expenses (2024 - 2026)

BridgeBio Oncology Therapeutics has reported Other Accumulated Expenses for 3 years, with the latest figure at $545000.0 in Q1 2026.

• Quarterly Other Accumulated Expenses changed N/A year-over-year to $545000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $545000.0 (changed N/A YoY) and the FY2025 annual result came in at $240000.0, up 44.58% from the prior year.
• Other Accumulated Expenses climbed to $545000.0 in Q1 2026 per BBOT's latest filing, from $240000.0 in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $545000.0 in Q1 2026 and troughed at $166000.0 in Q4 2024.
• A 3-year average of $282250.0 and a median of $209000.0 in 2025 frame the typical range for Other Accumulated Expenses.
• The widest YoY moves for Other Accumulated Expenses: up 44.58% in 2025, down 44.58% in 2025.
• Over 3 years, Other Accumulated Expenses stood at $166000.0 in 2024, then jumped by 44.58% to $240000.0 in 2025, then surged by 127.08% to $545000.0 in 2026.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $545000.0, $240000.0, and $178000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.